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ABSTRACT
The presence of IgE antibodies to the allergens rBetv1
and rBetv2 was investigated in the sera of 99 patients
with specific IgE to apple extract by comparing a group of
43 patients who had oral allergy syndrome (OAS) after
ingestion of apple with a group of 56 patients without
OAS who had only seasonal respiratory symptoms. The
incidence of the presence of IgE antibodies to rBetv1 
was 88.1%. All patients had levels of IgE to apple extract
greater than 0.35 kU/L. After eating apple, patients
allergic to birch pollen with OAS showed significantly
higher levels of IgE to apple extract and rBetv1 than
patients without OAS (P = 0.007 and P = 0.0002, res-
pectively). Twenty of 56 patients (35.7%) in the group
without OAS who produced specific IgE to apple did not
have specific IgE against rBetv1 and rBetv2 and were
symptomless after eating apple. In conclusion, patients
allergic to birch pollen with specific IgE to rBetv1 showed
a significantly elevated frequency of apple allergy. In con-
trast, our results show that fruit-related symptoms require
not only high specific serum IgE levels, but a strong cellu-
lar sensitization to birch pollen allergens, together with an
increased cellular reactivity to apple allergens.
Key words: apple, oral allergy syndrome, rBetv1,
rBetv2.
INTRODUCTION
It is well known that patients with a type I allergy to birch
pollen also suffer from intolerance to apple, which gives
rise to local symptoms, with or without systemic reactions,
on direct contact with the oral mucosa. The term currently
used to describe the complex of clinical features is oral
allergy syndrome (OAS). The major birch pollen allergen
rBetv1 and a homologous 18 kDa apple protein are
responsible for the majority of allergenic cross-reactions
between birch pollen and apples.1
The purpose of the present study was to determine the
frequency of IgE antibodies to rBetv1 and rBetv2 in
patients with specific IgE to apple, with and without OAS.
In this way, we hoped to establish whether the detection of
rBetv1- and rBetv2-specific IgE antibodies could be a
helpful tool in the diagnosis of OAS in pollinic patients.
METHODS
The present retrospective study comprised 99 patients
(48 males and 51 females) with a mean age of 37 years
(range 9–64 years). All had specific IgE to apple (mean
5.2 kU/L; range, 0.37–53.9 kU/L). The presence of
apple-specific IgE was sufficient for inclusion of patients
into the study. The clinical symptoms included rhinocon-
junctivitis, asthma, urticaria and OAS.
Specific serum IgE antibodies to apple extract and
recombinant allergens rBetv1 and rBetv2 were measured
by the Immuno CAP System (Pharmacia-Upjohn, Uppsala,
Sweden). The results are given in kU/L and CAP classes
from 0 to 6. A value greater than 0.35 kU/L (CAP classes
1–6) was regarded as a positive result.
Proportions were compared using a two-tailed Chi-
squared test with Yates’ correction. The Mann–Whitney
U-test was used for comparison of two unpaired groups.
Results are expressed as the median value. P < 0.05 was
considered significant.
RESULTS
The incidence of the presence of IgE antibodies to rBetv1
was 88.1%. All patients had IgE to apple extract. Of
the 43 patients with OAS, 38 (88.3%) had IgE to rBetv1;
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26 (60.4%) showed IgE binding to rBetv1, but not to
rBetv2; 12 (27.9%) had sera containing IgE antibodies to
rBetv2 in addition to rBetv1; three (7.0%) had sera that
reacted to rBetv2, but not rBetv1; and two (4.7%) did not
show specific IgE against either of the recombinant aller-
gens. Interestingly, 20 of 56 patients (35.7%) without
OAS but with a positive CAP result for apple (mean
1.9 kU/L, range 0.39–3.28 kU/L) did not report specific
IgE against rBetv1 and rBetv2 and did not have symptoms
following ingestion of apple. This is a common obser-
vation in this geographic area. All these patients showed
specific IgE to grass pollen, Olea europaea and mug-
wort, reflecting the high incidence of simultaneous
sensitization to these allergens in the region studied.
The serologic features of patients with and without
OAS are summarized in Table 1. Median values of IgE
levels to apple, rBetv1 and rBetv2 are shown in Table 2.
Birch pollen-allergic patients with symptoms after eating
apple showed significantly higher IgE levels to apple
extract (P = 0.007) and rBetv1 (P = 0.0002) than patients
without OAS.
DISCUSSION
Our results support the view that the 18 kDa protein
represents the major allergen of the apple and that aller-
genic epitopes of the apple protein are present on
rBetv1.2 However, the finding of the occurrence of IgE to
apple in patients lacking IgE to rBetv1 and rBetv2 shows
the complexity of this matter. Recently, a third group of
proteins not homologous to rBetv1 and rBetv2, with a
molecular weight range of 46–60 kDa and displaying
IgE cross-reactivity shared by birch, mugwort pollen and
celery, has been identified.2 According to the literature,
these allergens seem to represent homologs of Artv1.3
Bauer et al.2 showed that the 60 kDa protein seems to
represent a non-cross-reacting mugwort-specific aller-
gen. Other mugwort pollen-specific allergens are the
28 kDa allergen and other proteins of 12 kDa and lower.
Hence, extracts of birch pollen and celery share three
groups of molecules and mugwort pollen and celery have
two of these molecules in common.
Our finding of significantly increased levels of IgE
against rBetv1 in patients with OAS and specific IgE to
apple confirms the results of previous studies.1–5 The
observation that, of 99 patients with specific IgE to
apple extract, only 43 patients (43.4%) reported typical
symptoms after eating apples suggests that fruit-related
symptoms require not only high specific serum IgE
levels, but a strong cellular sensitization of birch pollen
allergens, together with an increased cellular reactivity
to apple allergens, as previously demonstrated.6,7
Although the present data suggest that there is signifi-
cant cross-reactivity with rBetv1, the data also suggest
that, in more than one-third of patients, sensitivity to
rBetv2 or other allergens plays a significant role.8
218 RE ROSSI ET AL.
Table 1 Serologic characteristics of 99 patients with specific IgE to apple and its relationship with specific IgE against rBetv1
and rBetv2
P values determined using a Chi-squared test with Yates’ correction; OAS, oral allergy syndrome.
Table 2 Levels of IgE to rBetv1, rBetv2 and F49 (apple)
Data show the median value with numbers in parentheses indicating the 25th and 75th percentiles. *The mean value for the ratio rBetv1:rBetv2
is shown. Statistical comparisons were made using the Mann–Whitney U-test; OAS, oral allergy syndrome.
rBetv1 positive rBetv1 positive rBetv1 negative rBetv1 negative
rBetv2 negative rBetv2 positive rBetv2 positive rBetv2 negative
n % n % n % n %
OAS 26 60.4 12 27.9 3 6.98 2 4.4
Non-OAS 11 19.6, P < 0.0011 12 21.4, P < 0.01 13 23.2, P < 0.0011 20 35.7, P < 0.001
Patients with Patients without
OAS (n = 43) OAS (n = 56) P
F49 (kU/L) 3.4 (1.5–6.9) 1.5 (0.6–4.8) 0.007
rBetv1 (kU/L) 31.9 (8.0–48.4) 0.1 (0.1–8) 0.0002
rBetv2 (kU/L) 0.1 (0.1–2.1) 0.1 (0.1–3.9) NS
rBetv1:rBetv2* 25.1 1.7 0.0002
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